---
schema_version: "secwatch.filing_event.v1"
accession: "0001425450-24-000077"
form_type: "8-K"
ticker: "KIDS"
cik: "0001425450"
company_name: "ORTHOPEDIATRICS CORP"
filed_at: "2024-08-05T23:59:59+00:00"
generated_at: "2026-05-31T13:03:12.083927+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# OrthoPediatrics reports record Q2 revenue up 33% to $52.8M; net loss widens to $6.0M

## Summary
- Q2 2024 revenue $52.8M (+33% YoY); U.S. +39%, Intl +16%. Trauma & Deformity +37%, Scoliosis +26%.
- Net loss $6.0M ($0.26/share) vs $2.9M loss ($0.13) in Q2 2023; Adjusted EBITDA $2.6M vs $2.3M.
- Reaffirmed FY2024 revenue guidance $200M-$203M (34-36% growth); EBITDA guidance $8M-$9M.
- Announced $100M financing (term loan + convertible notes) from Braidwell LP; expects to close Aug 12, 2024.
- Approved $5M stock buyback; cash $30.9M (down from $82.3M Dec 2023) due to $5.5M one-time payments.

## SEC filing metadata
- accession: 0001425450-24-000077
- form_type: 8-K
- ticker: KIDS
- cik: 0001425450
- company_name: ORTHOPEDIATRICS CORP
- filed_at: 2024-08-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1425450/000142545024000077/0001425450-24-000077-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1425450/000142545024000077/kids-20240805.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001425450-24-000077
- JSON: https://secwatch.observer/filing/0001425450-24-000077.json
- Plain text: https://secwatch.observer/filing/0001425450-24-000077.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.